<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149211</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A304-HIV</org_study_id>
    <nct_id>NCT03149211</nct_id>
  </id_info>
  <brief_title>To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults</brief_title>
  <official_title>A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase III study is to evaluate the efficacy, safety and tolerability of&#xD;
      UB-421 monotherapy in suppressing viral rebound in HIV-1 infected adults undergoing&#xD;
      antiretroviral treatment interruption.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase III study to evaluate the efficacy, safety and tolerability of&#xD;
      UB-421 monotherapy in suppressing viral rebound while replace HAART in virally suppressed&#xD;
      HIV-1 infected adults. In this study, approximately 375 subjects on stable HAART treatment&#xD;
      will be randomized to receive either continuing HAART treatment alone (Cohort 1) or UB-421 as&#xD;
      the monotherapy (Cohort 2) in 1:2 ratio. For Cohort 1, subjects will receive current standard&#xD;
      HAART treatment as the active control group. For Cohort 2, UB-421 will be administered to&#xD;
      enrolled subjects without HAART treatment in the Cohort 2 during the 26-week treatment&#xD;
      period. After treatment period, both cohort 1 and cohort 2 enter 22-week follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants without virologic failure</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentration of UB-421 in Cohort 2</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of UB-421 in Cohort 2</measure>
    <time_frame>30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive current standard HAART treatment as the active control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UB-421</intervention_name>
    <description>Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>dB4C7 mAb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>current standard HAART treatment</intervention_name>
    <description>Subjects will receive current standard HAART treatment as the active control group.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 sero-positive&#xD;
&#xD;
          -  Aged 20 years or older&#xD;
&#xD;
          -  Were not breastfeeding for women&#xD;
&#xD;
          -  Subjects with a negative serum pregnancy test result at screening visit for women of&#xD;
             childbearing potential&#xD;
&#xD;
          -  Subjects agree on using birth control barrier (female or male condom) during the&#xD;
             entire study period&#xD;
&#xD;
          -  Subjects sign the informed consent before undergoing any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active infection except for HIV, and required immediate therapy&#xD;
&#xD;
          -  Any active AIDS-defining illness per Category B and Category C conditions according to&#xD;
             the U.S. Centers for Disease Control and Prevention (CDC) Classification System for&#xD;
             HIV Infection&#xD;
&#xD;
          -  Any significant diseases (other than HIV-1 infection) or clinically significant&#xD;
             findings, including psychiatric and behavioral problems, determined from screening,&#xD;
             medical history, and/or physical examination that, in the investigator's opinion,&#xD;
             would preclude the subject from participating in this study&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Any alcohol or illicit drug used, according to the investigator's opinion, will&#xD;
             interfere with the subject's ability to comply with the dosing, visit schedules and&#xD;
             protocol evaluations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allen Tsai</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3641</phone_ext>
    <email>allen.tsai@unitedbiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zhonghao shi</last_name>
    <phone>+886-3-668-4800</phone>
    <phone_ext>3204</phone_ext>
    <email>zhonghao.shi@unitedbiopharma.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>UB-421</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

